GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Beijing Tiantan Biological Products Corp Ltd (SHSE:600161) » Definitions » Total Assets

Beijing Tiantan Biological Products (SHSE:600161) Total Assets : ¥14,792 Mil (As of Mar. 2024)


View and export this data going back to 1998. Start your Free Trial

What is Beijing Tiantan Biological Products Total Assets?

Beijing Tiantan Biological Products's Total Assets for the quarter that ended in Mar. 2024 was ¥14,792 Mil.

Warning Sign:

If a company builds assets at 21.2% a year, faster than its revenue growth rate of 8.7% over the past 5 years, it means that the company may be getting less efficient.

During the past 12 months, Beijing Tiantan Biological Products's average Total Assets Growth Rate was 7.10% per year. During the past 3 years, the average Total Assets Growth Rate was 18.20% per year. During the past 5 years, the average Total Assets Growth Rate was 21.20% per year. During the past 10 years, the average Total Assets Growth Rate was 6.90% per year.

During the past 13 years, Beijing Tiantan Biological Products's highest 3-Year average Total Assets Growth Rate was 44.30%. The lowest was -12.90%. And the median was 19.50%.

Total Assets is connected with ROA %. Beijing Tiantan Biological Products's annualized ROA % for the quarter that ended in Mar. 2024 was 8.74%. Total Assets is also linked to Revenue through Asset Turnover. Beijing Tiantan Biological Products's Asset Turnover for the quarter that ended in Mar. 2024 was 0.08.


Beijing Tiantan Biological Products Total Assets Historical Data

The historical data trend for Beijing Tiantan Biological Products's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Beijing Tiantan Biological Products Total Assets Chart

Beijing Tiantan Biological Products Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6,314.41 7,585.21 11,577.63 12,929.11 14,188.06

Beijing Tiantan Biological Products Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13,512.92 13,881.24 14,596.79 14,188.06 14,791.83

Beijing Tiantan Biological Products Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Beijing Tiantan Biological Products's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Assets=Total Equity (A: Dec. 2023 )+Total Liabilities (A: Dec. 2023 )
=12754.37+1433.687
=14,188

Beijing Tiantan Biological Products's Total Assets for the quarter that ended in Mar. 2024 is calculated as

Total Assets=Total Equity (Q: Mar. 2024 )+Total Liabilities (Q: Mar. 2024 )
=13186.497+1605.335
=14,792

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Beijing Tiantan Biological Products  (SHSE:600161) Total Assets Explanation

Total Assets is connected with ROA %.

Beijing Tiantan Biological Products's annualized ROA % for the quarter that ended in Mar. 2024 is

ROA %=Net Income (Q: Mar. 2024 )/( (Total Assets (Q: Dec. 2023 )+Total Assets (Q: Mar. 2024 ))/ count )
=1266.696/( (14188.057+14791.832)/ 2 )
=1266.696/14489.9445
=8.74 %

Note: The Net Income data used here is four times the quarterly (Mar. 2024) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Beijing Tiantan Biological Products's Asset Turnover for the quarter that ended in Mar. 2024 is

Asset Turnover
=Revenue (Q: Mar. 2024 )/( (Total Assets (Q: Dec. 2023 )+Total Assets (Q: Mar. 2024 ))/ count )
=1221.955/( (14188.057+14791.832)/ 2 )
=1221.955/14489.9445
=0.08

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Beijing Tiantan Biological Products Total Assets Related Terms

Thank you for viewing the detailed overview of Beijing Tiantan Biological Products's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Beijing Tiantan Biological Products (SHSE:600161) Business Description

Traded in Other Exchanges
N/A
Address
No. 4 Sanjianfang South Li, Zhongdan Center, Beijing, CHN, 100024
Beijing Tiantan Biological Products Corp Ltd is a China-based company engaged in the research and development, manufacturing, sales and consulting services for blood products. The company's blood products include Shanghai Blood Human Albumin, Shanghai blood system intravenous injection of human immunoglobulin, Guizhou blood human albumin, Rongsheng human albumin, Guizhou blood system static injection immunoglobulin, Rongsheng tetanus human immunoglobulin and others.
Executives
Wang Jian Ming Supervisors
Liu Ya Na Directors, senior managers
Fu Dao Xing Directors, senior managers
He Yan Lin Directors, senior managers
Hu Li Gang Director
Ci Xiang senior management
Yang Hui Chuan Director
Zhang Yi senior management
Wu Zhen Shan senior management

Beijing Tiantan Biological Products (SHSE:600161) Headlines

No Headlines